Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR–NRF2 Axis in Human Keratinocytes
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147910 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Gaku Tsuji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka 812-8582, Japan. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Keratinocytes, Interleukin-1 Receptor-Like 1 Protein, Receptors, Aryl Hydrocarbon. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Health, Labour and Welfare, Japan, Ministry of Health, Labour and Welfare, Japan.
Abstract (Originalsprache)
Difamilast, a phosphodiesterase 4 (PDE4) inhibitor, has been shown to be effective in the treatment of atopic dermatitis (AD), although the mechanism involved remains unclear. Since IL-33 plays an important role in the pathogenesis of AD, we investigated the effect of difamilast on IL-33 activity. Since an in vitro model of cultured normal human epidermal keratinocytes (NHEKs) has been utilized to evaluate the pharmacological potential of adjunctive treatment of AD, we treated NHEKs with difamilast and analyzed the expression of the suppression of tumorigenicity 2 protein (ST2), an IL-33 receptor with transmembrane (ST2L) and soluble (sST2) isoforms. Difamilast treatment increased mRNA and protein levels of sST2, a decoy receptor suppressing IL-33 signal transduction, without affecting ST2L expression. Furthermore, supernatants from difamilast-treated NHEKs inhibited IL-33-induced upregulation of TNF-α, IL-5, and IL-13 in KU812 cells, a basophil cell line sensitive to IL-33. We also found that difamilast activated the aryl hydrocarbon receptor (AHR)–nuclear factor erythroid 2-related factor 2 (NRF2) axis. Additionally, the knockdown of AHR or NRF2 abolished the difamilast-induced sST2 production. These results indicate that difamilast treatment produces sST2 via the AHR–NRF2 axis, contributing to improving AD symptoms by inhibiting IL-33 activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka 812-8582, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
ORCID-Profile: Ayako Yumine, Masaki Takemura
Förderung
- The Ministry of Health, Labour and Welfare, Japan
- Ministry of Health, Labour and Welfare, Japan
Zitieren
APA
Tsuji, G., Yumine, A., Kawamura, K., Takemura, M., Kido-Nakahara, M., Yamamura, K., & Nakahara, T. (2024). Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR–NRF2 Axis in Human Keratinocytes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147910
Vancouver
Tsuji G, Yumine A, Kawamura K, Takemura M, Kido-Nakahara M, Yamamura K, et al. Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR–NRF2 Axis in Human Keratinocytes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147910
BibTeX
@article{Tsuji2024,
author = {Tsuji, Gaku and Yumine, Ayako and Kawamura, Koji and Takemura, Masaki and Kido-Nakahara, Makiko and Yamamura, Kazuhiko and Nakahara, Takeshi},
title = {Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR–NRF2 Axis in Human Keratinocytes},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147910}
}
EUVIMED